Boston Scientific’s recent acquisition spree
Boston Scientific (BSX) has made six acquisitions to date in 2018, with the most recent being the acquisition of Cryterion Medical it announced on July 5. The acquisition aims to expand the company’s electrophysiology product portfolio.
In April, Boston Scientific announced the acquisitions of nVision Medical and Securus Medical. nVision Medical is expected to boost Boston Scientific’s growth in the area of urology and pelvic health as the acquisition adds the first and only early diagnosis device for ovarian cancer to BSX’s portfolio. For details, read How BSX Is Set to Benefit from Its nVision Medical Acquisition.
The Securus Medical acquisition will add to BSX’s cardiac rhythm product portfolio a thermal monitoring system for esophageal temperature measurement on a continuous basis for use during cardiac ablation procedures. The FDA approved the device in 2016.
In January, Boston Scientific announced its acquisition of Millipede in the structural heart space.
Boston Scientific’s inorganic growth strategy
Boston Scientific has been focused on expansion across high-growth markets and innovative product platforms. The company has made some key acquisitions recently. Boston Scientific’s CEO has reiterated time and again that the company’s capital allocation strategy has prioritized mergers and acquisitions in recent years. The company expects its recent strategic acquisitions to strengthen its core businesses, which are growing quickly. Boston Scientific expects these acquisitions to tap new market opportunities worth over $16 billion by 2021.
Check out all the data we have added to our quote pages. Now you can get a valuation snapshot, earnings and revenue estimates, and historical data as well as dividend info. Take a look!